SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies strengthens on getting nod to sell Meropenem in Australia

19 May 2014 Evaluate

Venus Remedies is currently trading at Rs 318.35, up by 16.60 points or 5.50% from its previous closing of Rs 301.75 on the BSE.

The scrip opened at Rs 305.00 and has touched a high and low of Rs 325.00 and Rs 304.00 respectively. So far 59999 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 350.00 on 28-Apr-2014 and a 52 week low of Rs 140.00 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs 325.25 and Rs 300.00 respectively. The current market cap of the company is Rs 362.71 crore.

The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 8.75% and 47.26% respectively.

Venus Remedies has received marketing authorization for its antibiotic drug Meropenem from Australian regulator TGA. The company has also tied-up with Lupin to market this drug in Australia.The company planning to roll out the drug by the third quarter of 2014.

Meropenem is an off-patent antibacterial agent of the Carbapenem class of antibiotics that caters to diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

 

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×